Clinical Effectiveness of the Fixed‐Dose vs Free‐Dose Triple Combinations in Patients with Uncontrolled Arterial Hypertension

ORIGINAL ARTICLE
D. Yu. Shukurova, G. A. Khamidullaeva, G. Zh. Abdullaeva, Kh. F. Yusupova, A. D. Yuldasheva, Sh. Fayzullaeva, Zh. B. Safarov, Sh. M. Masharipov

 
For citation: Shukurova DYu, Khamidullaeva GA, Abdullaeva GZh, Yusupova KhF, Yuldasheva AD, Fayzullaeva Sh, Safarov ZhB, Masharipov ShM. Clinical Effectiveness of the Fixed‐Dose vs Free‐Dose Triple Combinations in Patients with Uncontrolled Arterial Hypertension. International Journal of Biomedicine. 2024;14(2):253-259. doi:10.21103/Article14(2)_OA2
 
Originally published June 5, 2024
 

Abstract: 

Background: The purpose of our study was a comparative assessment of the antihypertensive effectiveness of 2 triple combination antihypertensive therapy (AHT) regimens in a free-dose and fixed-dose combination of perindopril, indapamide, and amlodipine in hypertensive patients with high cardiovascular risk and a poor response to the 2-drug combinations in the clinic practice.
Methods and Results: Our study included 143 patients (79 men and 88 women) with arterial hypertension (AH) Grades 1-3 (ESC/ESH, 2018) and high cardiovascular risk who did not achieve the target blood pressure (TBP) on dual combination AHT. The mean age of patients was 55.76±9.35 years; the average duration of AH was 10.69±6.61 years. All patients underwent the examinations according to the 2018 ESC/ESH Guidelines for the management of arterial hypertension.
Patients included in the study were divided into 2 groups using the envelope method: Group 1 (n=84) received a fixed-dose, triple combination of perindopril, indapamide, and amlodipine; Group 2 (n=83) received a free-dose combination of these drugs. In both groups, treatment began after discontinuation of previous therapy, with a low dose of a triple combination of antihypertensive drugs (perindopril [5 mg/day], indapamide [1.25 mg/day], amlodipine [5 mg/day]) in the form of a fixed or free combination. The initial doses of perindopril/indapamide/amlodipine in both groups were not statistically different: 6.9±2.4/1.74±0.6/7.1±2.4mg/day in Group 1 and 6.9±2.7/1.95±0.6/7.1±2.5 mg/day in Group 2. After 4 weeks of therapy, if necessary, the doses of drugs were increased, starting with perindopril; the next adjustment of drug doses was carried out after 12 weeks of therapy. The final treatment results were determined after 24 weeks of AHT.
Target blood pressure (TBP) of <140/90 mmHg was reached by 94.4% of patients in Group 1 and 83.3% in Group 2 (χ²=7.471, Р=0,006); TBP of <130/80 mmHg was reached by 70% of patients in Group 1 and 42% in Group 2 (χ²=11.61, Р=0,0001).  A significant improvement in the diurnal BP profile was also revealed during treatment. According to ABPM data, both groups achieved TBP in terms of the average 24-h and average daytime systolic blood pressure (SBP) and diastolic blood pressure (DBP). Regarding average nighttime SBP and DBP and normalization of average nighttime diastolic blood pressure variability, target values were achieved only in Group 1(P=0.028).
In both groups, 24-week triple-combination therapy led to a significant decrease in central SBP, central DBP, and pulse wave velocity (PWV). At the same time, the positive dynamics of central SBP were more pronounced in Group 1 than in Group 2 (Table 4), and PWV in Group 1 reached standard values.
Conclusion: The results of our study showed that in the treatment of uncontrolled hypertension on previous therapy in AH patients with high cardiovascular risk, a single-pill triple combination of the ACEI perindopril, the CCB amlodipine, and the thiazide-like diuretic indapamide contributed to the effective daily blood pressure control, the improvement of diurnal blood pressure profile, and a positive effect on central blood pressure and PWV, thereby having a positive impact on the prognosis and quality of life of AH patients with high cardiovascular risk.

Keywords: 
arterial hypertension • antihypertensive therapy • target blood pressure • single-pill triple combination
References: 
  1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475. PMID: 30165516.
  2. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26. Erratum in: J Hypertens. 2024 Jan 1;42(1):194. PMID: 37345492.
  3. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010 May;24(5):336-44. doi: 10.1038/jhh.2009.76. Epub 2009 Oct 1. PMID: 19798089.
  4. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J; SPRINT Research Group. Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med. 2017 Aug 24;377(8):733-744. doi: 10.1056/NEJMoa1611179. PMID: 28834483; PMCID: PMC5706112.
  5. Wright JT Jr, Whelton PK, Johnson KC, Snyder JK, Reboussin DM, Cushman WC, Williamson JD, Pajewski NM, Cheung AK, Lewis CE, Oparil S, Rocco MV, Beddhu S, Fine LJ, Cutler JA, Ambrosius WT, Rahman M, Still CH, Chen Z, Tatsuoka C; SPRINT Research Group. SPRINT Revisited: Updated Results and Implications. Hypertension. 2021 Dec;78(6):1701-1710. doi: 10.1161/HYPERTENSIONAHA.121.17682. Epub 2021 Nov 10. PMID: 34757768; PMCID: PMC8824314.
  6. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sep 4;310(9):959-68. doi: 10.1001/jama.2013.184182. PMID: 24002282.
  7. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Jan;96(4):e5641. doi: 10.1097/MD.0000000000005641. PMID: 28121920; PMCID: PMC5287944.
  8. Bramlage P, Böhm M, Volpe M, Khan BV, Paar WD, Tebbe U, Thoenes M. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010 Sep;12(9):666-77. doi: 10.1111/j.1751-7176.2010.00322.x. PMID: 20883226; PMCID: PMC8673112.
  9. Stafylas P, Kourlaba G, Hatzikou M, Georgiopoulos D, Sarafidis P, Maniadakis N. Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components. Cost Eff Resour Alloc. 2015 Jun 9;13:10. doi: 10.1186/s12962-015-0036-x. PMID: 26097434; PMCID: PMC4474457.
  10. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, Zoungas S, Patel A, Williams B, Harrap S. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension. 2014 Feb;63(2):259-64. doi: 10.1161/HYPERTENSIONAHA.113.02252. Epub 2013 Dec 9. Erratum in: Hypertension. 2015 Jul;66(1):e2. PMID: 24324048.
  11. Yamout H, Bakris GL. Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus. Hypertension. 2014 Feb;63(2):220-1. doi: 10.1161/HYPERTENSIONAHA.113.02659. Epub 2013 Dec 9. PMID: 24324049.
  12. Mahfoud F, Kieble M, Enners S, Kintscher U, Laufs U, Böhm M, Schulz M. Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clin Res Cardiol. 2023 Feb;112(2):197-202. doi: 10.1007/s00392-022-01993-5. Epub 2022 Feb 27. PMID: 35220445; PMCID: PMC9898344.
  13. Syed YY. Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. Am J Cardiovasc Drugs. 2022 Mar;22(2):219-230. doi: 10.1007/s40256-022-00521-0. Epub 2022 Mar 8. Erratum in: Am J Cardiovasc Drugs. 2022 May;22(3):355. PMID: 35257306; PMCID: PMC8964631.
  14. Nedogoda SV, Stojanov VJ. Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial. Cardiol Ther. 2017 Jun;6(1):91-104. doi: 10.1007/s40119-017-0085-7. Epub 2017 Feb 8. PMID: 28181192; PMCID: PMC5446818.
  15. Burnier M, Redon J, Volpe M. Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. High Blood Press Cardiovasc Prev. 2023 Mar;30(2):109-121. doi: 10.1007/s40292-023-00563-8. Epub 2023 Jan 25. PMID: 36696054; PMCID: PMC10090015.
  16. Ábrahám G, Dézsi CA. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. Adv Ther. 2017 Jul;34(7):1753-1763. doi: 10.1007/s12325-017-0572-1. Epub 2017 Jun 23. PMID: 28646394.
  17. Mareev VY, Minina YV, Begrambekova YL, Levin AM. [Therapeutic approaches to the Rational Use of trip-le combination therapy with a fixed combination of amlodipine, indapamide and perindopril arginine (TRIPLE COMBINATION) in patients with hypertension who do not control blood pressure on conventional treatment. (Description and main results of the TRIO program)]. Kardiologiia. 2020 Jun 3;60(5):1149. Russian. doi: 10.18087/cardio.2020.5.n1149. PMID: 32515706.
  18. Tóth K; PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014 Apr;14(2):137-45. doi: 10.1007/s40256-014-0067-2. Erratum in: Am J Cardiovasc Drugs. 2014 Jun;14(3):239. PMID: 24590580.
  19. Logunova N, Khomitskaya Y, Karpov Y, et al. Antihypertensive efectiveness and tolerability of perindopril/indapamide/amlodipine triple single-pill combination in the treatment of patients with arterial hypertension (TRICOLOR). J Hypertens. 2021;39(Suppl 1): e373.
  20. Páll D, Szántó I, Szabó Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin Drug Investig. 2014 Oct;34(10):701-8. doi: 10.1007/s40261-014-0223-0. PMID: 25212574.
  21. Masharipov Sh, Ataniyazov Kh, Shukurova D, Khamidullaeva G, Abdullaeva G, Kurbanov R. The Effectiveness of the Triple Fixed-Dose Combination Therapy in the Management of Uncontrolled Arterial Hypertension. International Journal of Biomedicine. 2020;10(4):334-341. doi: 10.21103/Article10(4)_OA1
  22. Mbanya A, Ackbarkhan A, Mittoo MY, Ramamonjisoa HA, Ramilitiana B, Ranivoharisoa EM, Ratsimbazafy SJN, Mbanya JC. Use of Perindopril Arginine/Indapamide/Amlodipine in the Management of Hypertension in Two Sub-Saharan African Island Countries of Madagascar and Mauritius. Adv Ther. 2022 Jun;39(6):2850-2861. doi: 10.1007/s12325-022-02134-0. Epub 2022 Apr 18. PMID: 35438448; PMCID: PMC9122888.
  23. Mazza A, Lenti S, Schiavon L, Sacco AP, Dell'Avvocata F, Rigatelli G, Ramazzina E. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv Ther. 2017 Apr;34(4):975-985. doi: 10.1007/s12325-017-0511-1. Epub 2017 Mar 15. PMID: 28299716.
  24.  Larina V, Orlov D, Litvin A. Efectiveness of a fxed combination of three antihypertensive drugs in outpatients with hypertension. J Hypertens. 2019;37(Suppl 1): e250.

Download Article
Received February 3, 2024.
Accepted March 14, 2024.
©2024 International Medical Research and Development Corporation.